The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.
Retinoids, like tretinoin, may enhance minoxidil absorption and effectiveness on the scalp. Over-the-counter retinols lack strong evidence for similar benefits.
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
The solution contains minoxidil, finasteride, azelaic acid, caffeine, retinoicacid, and procapil. Users suggest minoxidil with tretinoin and a 5-alpha reductase inhibitor, while dismissing retinoic and azelaic acids as unnecessary.
The conversation discusses using Tretinoin for treating androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
RU58841 from rudirect caused more hair shedding and itch, while anageninc's RU58841 improved the situation. Users are concerned about the quality and authenticity of RU58841 from different suppliers, including those from China.
Tretinoin can make minoxidil more effective for hair loss treatment, but some users did not see improved hair density with this combination and had better results with dutasteride.
Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.
A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.
Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.
The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.
The conversation is about someone who had success using retinol with minoxidil for hair growth, but experienced shedding with Retin A (tretinoin). They are asking if others have tried retinol with minoxidil and what their results were.
Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.
Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.
The conversation discusses why CB-03-01, a potential hair loss treatment, isn't widely discussed despite evidence of its effectiveness and safety. Some users mention other treatments like melatonin, procianidin b2, and RU58841, debating their effectiveness and safety.
A user is using Minoxidil, finasteride, saw palmetto, and Minimalist RCP serum to address hair thinning, with some success but concerns about the long-term benefits of Minimalist. They plan to continue Minoxidil and finasteride for another year before considering a hair transplant.
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
The user is seeking advice on a hair loss treatment called Ell Cranell, which contains Alfatradiol. Another user shared information from a study stating that Alfatradiol only slows down or stabilizes hair loss, but does not increase hair density or thickness.